Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;50(3):799-807.
doi: 10.1002/hep.23054.

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

Affiliations

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

Bastian Hoechst et al. Hepatology. 2009 Sep.

Abstract

Several immune suppressive mechanisms that evade the host immune response have been described in patients with hepatocellular carcinoma (HCC); one of these mechanisms is expansion of myeloid-derived suppressor cells (MDSCs). MDSCs have been shown to inhibit T cell responses in tumor-bearing mice, but little is known about these cells in humans. Here, we have analyzed and characterized the effect of MDSCs on the innate immune system, in particular, their interaction with natural killer (NK) cells in patients with HCC. MDSCs from patients with HCC inhibited autologous NK cell cytotoxicity and cytokine secretion when cultured together in vitro. This suppression was dependent on cell contact, but did not rely on the arginase activity of MDSCs, which is a hallmark function of these cells. However, MDSC-mediated inhibition of NK cell function was dependent mainly on the NKp30 on NK cells.

Conclusion: Our study suggests a new role for MDSCs in patients with HCC in disarming the innate immune system and further contributing to the immune suppressor network in these patients. These findings have important implications when designing immunotherapy protocols.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: Nothing to report

Figures

Fig. 1.
Fig. 1.
NK cell cytotoxicity is reduced in patients with HCC. NK cells were FACS-sorted from PBMCs of either healthy donors (n = 10) or patients with HCC (n = 10), or from tumor-infiltrating lymphocytes (n = 5) by gating on CD56+CD3 population and used in a 51Cr-release assay against K562 target cells. Figure shown is average of four independent experiments (*P < 0.05).
Fig. 2.
Fig. 2.
CD14+HLA-DR−/low cells suppress NK cell function. (A) Purified NK cells were cultured in the absence or presence of different ratios of CD14+HLA-DR+ or CD14+HLA-DR−/low cells as indicated. After 12 hours, K562 cells were added at a ratio of 2.5:1 (E:T) and lysis was determined by standard 51Cr-release assay (P < 0.05). Shown are cumulative results from four independent experiments. (B) NK cells were stimulated with IL-2 and cultured in the presence or absence of CD14+HLA-DR−/low or CD14+HLA-DR+ cells as indicated. IFN-γ release was determined after 48 hours by ELISA. Shown are cumulative results from five independent experiments (*P < 0.05, **P < 0.001). NK cells cultured without IL-2 were used as background (arrow).
Fig. 3.
Fig. 3.
Intracellular cytokine analysis of CD14+HLA-DR−/low in the presence or absence of NK cells. (A) NK cells were stimulated with IL-2 and cultured either alone, with CD14+HLA-DR−/low, or with CD14+HLA-DR+ cells. IFN-γ was analyzed after 48 hours by intracellular FACS as shown in representative dot plots. (B) Cumulative results of three independent experiments are shown (*P < 0.05; **P < 0.001). Cytokine secretion was analyzed gating on CD14+ cells (black bars) and CD56+ cells (white bars).
Fig. 4.
Fig. 4.
Phenotypic analysis of NK cells and CD14+HLA-DR−/low cells upon coculture. Purified CD14+HLA-DR−/low or CD14+HLA-DR+ cells were cultured alone or with FACS-sorted autologous NK cells as indicated, and the expression of different surface markers (black lines) or isotype control (filled histograms) was analyzed by FACS. Representative histograms for (A) CD14+HLA-DR+, CD14+HLA-DR−/low or (B) NK cells are shown. Cumulative results of seven independent experiments for (C) HLA-DR and (D) NKp30 are shown (*P < 0.05; **P < 0.001, ***P < 0.0001).
Fig. 5.
Fig. 5.
Inhibition of IFN-γ production by MDSC is mainly cell contact–dependent, but independent of arginase and NO. (A) CD14+HLA-DR−/low cells were cocultured with NK cells as described and transwell inserts were used as indicated (white bar). IFN-γ secretion was determined by ELISA. Shown are cumulative results from three independent experiments (*P < 0.05). (B) Purified NK cells and CD14+HLA-DR−/low cells were cocultured in the absence or presence of N-omega-hydroxy-L-arginine (L-NOHA), N(G)-monomethyl-L-arginine (L-NMMA), 1-MT (10 μmol/L each), or media alone as indicated. IFN-γ production was measured by ELISA after 48 hours. Figure shown is a representative of three independent experiments. (C) Purified NK cells and CD14+HLA-DR−/low cells were cocultured for 36 hours. NK cells were reisolated, and a 51Cr-release assay against K562 target cells was performed. Shown is representative data from three independent experiments.
Fig. 6.
Fig. 6.
MDSC-mediated suppressive mechanism is independent of anti-CD94, anti-NKG2D, anti-NKp44, anti-HLA-DR, and anti-MHC class I. Purified NK cells were cultured with IL-2 in the absence or presence of different blocking antibodies as indicated. (A-E) IFN-γ secretion was measured in supernatants after coincubation in the presence of the indicated antibodies by ELISA. Shown are cumulative results from two independent experiments.
Fig. 7.
Fig. 7.
MDSC-mediated suppressive mechanism is dependent on NKp30. (A) NK cells were cultured with IL-2, CD14+HLA-DR−/low in the absence or presence of anti-NKp30 antibody or isotype control. IFN-γ secretion was measured by ELISA. Cumulative results ± SEM of three independent experiments are shown (*P < 0.05). (B) NK cells were cultured with CD14+HLA-DR−/low in the presence or absence of anti-NKp30 antibody or isotype control. K562 cells were added at a ratio of 2.5:1 (E:T) and lysis was measured. Cumulative results ± SEM of three independent experiments are shown.

Similar articles

Cited by

References

    1. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53–65. - PubMed
    1. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995;1:95–103. - PubMed
    1. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J,et al.Arginase-producingmyeloidsuppressorcellsinrenalcellcarcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044–3048. - PubMed
    1. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006;66:9299–9307. - PMC - PubMed
    1. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678–689. - PubMed

Publication types

Substances